Skip to main content
NewslettersWatchlist

Nervgen Pharma Corp(NGEN-X)
TSX Venture

Today's Change
Delayed Last Update
Day Low2.000
Day High2.150
Open:2.080
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Automated Summaries - The Globe and Mail
Closing Bell: Nervgen Pharma Corp down on Thursday (NGEN)
Newsfile
NervGen Engages Russo Partners LLC to Provide Public Relations Services
Newsfile
NervGen Pharma Reports 2023 Year-End Financial Results and Operational Updates
Newsfile
NervGen Completes $23 Million Bought Deal Financing
Newswire.ca
NERVGEN ANNOUNCES $20 MILLION BOUGHT DEAL OFFERING
Newsfile
NervGen Pharma Recognized as a Top 50 TSX Venture Exchange Company
Newsfile
NervGen Pharma Grants Stock Options
Newsfile
NervGen Pharma on Track to Complete Enrollment, Deliver Data Readout in Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury
AI-generated - The Globe and Mail
NervGen Pharma: Stocks Undervalued by Analyst Consensus on TSX-V (NGEN)
AllPennyStocks.com
Take Part in the Next Generation of Spinal Cord Injury Treatments with These Companies
Newsfile
NervGen Pharma Reports Q3 2023 Financial Results and Operational Updates
Newsfile
Neuroscientist and NervGen Pharma Scientific Founder, Dr. Jerry Silver, Interviewed on 'Remarkable People' Podcast Hosted by Tech Luminary Guy Kawasaki
AI-generated - The Globe and Mail
NervGen Pharma: Stocks Undervalued by Analyst Consensus on TSX-V (NGEN)
Newsfile
NervGen Pharma Receives Fast Track Designation for NVG-291 for the Treatment of Individuals with Spinal Cord Injury
Newsfile
NervGen Pharma Appoints John Ruffolo to Board of Directors
AllPennyStocks.com
Small Company Working on Big Breakthrough in Treating Spinal Cord Injuries
Newsfile
NervGen Pharma Announces First Subject Dosed in Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury
Newsfile
NervGen Pharma to Present at 2023 International Spinal Research Trust Network Meeting
Newsfile
NervGen Pharma to Present on Its Drug Candidate NVG-291 and Spinal Cord Injury at the H.C. Wainwright 25th Annual Global Investment Conference
Newsfile
NervGen Pharma to Present on its Drug Candidate NVG-291 and Spinal Cord Injury at Investor Conference
Newsfile
NervGen Pharma Reports Q2 2023 Financial Results and Operational Updates
Newsfile
NervGen Pharma to Proceed with Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury Having Completed FDA Review and Received IRB Approval
Newsfile
NervGen Pharma to Receive More than US$3 Million from Wings for Life to Support Upcoming Clinical Study in Spinal Cord Injury
Newsfile
NervGen Pharma to Present at Upcoming Investor Conferences
Newsfile
NervGen Pharma Extends the Expiry Date of Certain Stock Options
Newsfile
NervGen Pharma Grants Stock Options
Newsfile
NervGen Pharma Announces Results of Annual General Meeting of Shareholders
Newsfile
NervGen Pharma Reports Q1 2023 Results and Provides Operational Update Including Clinical Trials of Proprietary NVG-291
Newsfile
NervGen Pharma Presenting Phase 1b/2a Study Design at American Spinal Injury Association 50th Annual Scientific Meeting
Newsfile
NervGen Pharma Appoints Michael Kelly as President & Chief Executive Officer
Newsfile
NervGen Pharma Reports 2022 Year End Results and Provides Operational Update Including Plans to Initiate Phase 1b/2a Clinical Trial of Proprietary NVG-291 in Q3 2023
Newsfile
NervGen Pharma Grants Stock Options

Profile

NervGen Pharma Corp is a biotech company dedicated to creating innovative solutions for treating nerve damage and neurodegenerative diseases. NervGen is testing a new drug called NVG-291 in a Phase 1b/2a clinical trial. The company is developing drugs for treating spinal cord injury, multiple sclerosis, and Alzheimer's disease.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.